RGEN - Stocks to Watch in February
Earnings season is here. That means most public companies have reported or will soon report operating results for the quarter ended Dec. 31. For many, the next report will include full-year 2019 operating results and full-year 2020 guidance. The stakes are higher for some than for others.
For instance, investors are worried once again about the late-stage pipeline of Incyte (NASDAQ: INCY), which started the year by announcing that an important drug candidate failed a clinical trial. Can the company calm anxious investors?
Meanwhile, bioprocessing leader Repligen (NASDAQ: RGEN) has delivered impressive growth in recent years thanks to a bevy of completed acquisitions. Will the release of full-year 2020 revenue guidance suggest similar growth in the year ahead and help investors look past the pharma stock's premium valuation?